Sign In
×Jamjoom Pharma boosts presence in key markets, ramp up production: CEOArgaam Special13/05/2024
Senior execs of Aramco, SNB, eXtra, stc highest paid in 2023Argaam Special21/04/2024
Osool & Bakheet issues Q1 2024 earnings forecastArgaam20/04/2024
GIB Capital previews Q1 2024 earningsArgaam14/04/2024
Senior execs of Aramco, SNB, eXtra, stc highest paid in 2023Argaam Special21/04/2024
Highest-paid executives, board members of Saudi-listed firms in 2023Argaam Special16/04/2024
Jamjoom Pharma seen to post profit growth in Q4 2023Argaam Special20/02/2024
How did analysts view TASI performance, top picks for 2024?Argaam Special09/01/2024
How did analysts view Jamjoom Pharma’s Q3 financials?Argaam Special05/12/2023
Market Data
Last Trade | 133.00 |
Change | (2.20) |
Change (%) | (1.63) |
Open | 137.80 |
Low | 131.60 |
High | 137.80 |
Prev. Close | 135.20 |
Change (3M) | (11.33 %) |
Change (6M) | 25.95 % |
Volume | 165,929 |
Turnover | 22,223,198.00 |
Transactions | 1,788 |
Market Value | 9,310.00 |
Avg. Volume (3M) | 396,365.34 |
Avg. Turnover (3M) | 55,632,367.41 |
Avg. Transaction (3M) | 3,168.91 |
Change(12M) | n/a |
YTD | 15.65 % |
Event Date
|
Event
|
Venue
|
|
---|---|---|---|
25-03-2024
|
Conferences | - | |
25-03-2024
|
Financial results date | - | |
12-03-2024
|
General Assembly | - | |
07-11-2023
|
Financial results date | - | |
07-11-2023
|
Conferences | - | |
more |
Date | Research firm | Rating |
|
United Securities Company | Hold |
|
GIB Capital | Neutral |
|
Al Rajhi Capital | Overweight |
|
Al Rajhi Capital | Overweight |
Call Request